Blue Jet Healthcare Ltd (BLUEJET)
🎯 Key Takeaways
- Blue Jet Healthcare is a mid-sized pharmaceutical company operating in a mature segment of the healthcare industry, with strong historical profitability metrics (ROE 71.1%, ROCE 84.
- Revenue grew 24.9% QoQ to ₹293 in Q1FY27.
- ⚠️ Revenue volatility persists despite margin resilience, with three consecutive YoY declines raising concerns about demand sustainability in core pharma
- Market Cap
- ₹10,544
- P/E Ratio
- 41.1
- P/B Ratio
- 31.92
- ROE
- 71.1%
- ROCE
- 84.3%
- Debt/Equity
- 0.16
- Promoter
- 73.2%
📖 The Story
Blue Jet Healthcare is a mid-sized pharmaceutical company operating in a mature segment of the healthcare industry, with strong historical profitability metrics (ROE 71.1%, ROCE 84.3%) but facing near-term revenue headwinds. The company demonstrates financial resilience with conservative leverage (D/E 0.16) and consistent margin discipline, though its 1-year return of -11.3% reflects market sensitivity to sector-specific or execution-related pressures. Management appears focused on operational stability and shareholder returns amid a challenging revenue environment.
📰 What's Happening
In Q1 FY27 (August 3, 2026 filing), Blue Jet Healthcare reported revenue of ₹2,931 million, down 17% YoY but up 25% QoQ, with PAT margin expanding to 27% and EBITDA margin to 33%, indicating operational efficiency gains despite top-line pressure. The company raised ₹8,000 million via qualified institutional placement (QIP) during the quarter and received EcoVadis Silver Medal recognition for sustainability performance. Additionally, on August 3, 2026, the Board reappointed Akshay B Arora as Whole-Time Director and Executive Chairman for five years and Shiven Arora as Managing Director for five years, while KKC & Associates LLP was reappointed as statutory auditors. A dividend of ₹1.2 per share was declared, with the record date set for September 14, 2026, ahead of the 58th AGM scheduled for September 21, 2026, which will be conducted virtually with electronic voting only.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 165 | 192 | 235 | 293 |
| Operating Profit | 49 | 41 | 65 | 91 |
| OPM % | 29.7% | 21.3% | 27.6% | 31.2% |
| Net Profit | 52 | 40 | 64 | 78 |
| EPS | ₹3.01 | ₹2.32 | ₹3.71 | ₹4.51 |
The sequential revenue growth of 25% in Q1 FY27, following declines in the prior three quarters, suggests potential stabilization or early recovery in demand, possibly driven by product launches or inventory restocking. Despite a 17% YoY revenue drop, margins improved significantly — PAT margin rose to 27% from prior quarters and EBITDA to 33% — indicating effective cost management or favorable input cost dynamics. The ₹8,000 million QIP fundraise in Q1 FY27 provides a strong liquidity buffer and may support strategic investments or working capital needs without dilutive debt. The consistent quarter-on-quarter improvement in operating performance aligns with management’s focus on operational discipline, even as top-line volatility persists.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue or earnings growth in the latest filings. However, the Board’s reappointments of key leadership — Akshay B Arora and Shiven Arora — signal continuity in strategic direction. The company emphasized its commitment to sustainability and operational excellence through the BRSR report, though without quantitative targets. The upcoming 58th AGM on September 21, 2026, will be pivotal for shareholder approval of dividends and governance matters, but no strategic outlook beyond routine disclosures was included in recent filings.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2021 |
|---|---|
| Equity Capital | 10 |
| Reserves | 320 |
| Borrowings | 52 |
| Total Liabilities | 536 |
| Fixed Assets | 139 |
| Investments | 37 |
| Total Assets | 536 |
The company maintains a very strong balance sheet with negligible debt (D/E 0.16) and substantial equity reserves, reflecting a conservative capital structure. The ₹8,000 million raised via QIP in Q1 FY27 significantly bolsters liquidity and may be used for working capital, R&D, or strategic opportunities without increasing financial risk. There is no indication of capital expenditure or deleveraging activity in recent disclosures, suggesting capital is being preserved or allocated selectively. The strong equity base and low leverage provide flexibility for future investments or shareholder returns, though the lack of disclosed reinvestment plans limits visibility into growth deployment.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2021 |
|---|---|
| Operating | +129 |
| Investing | -51 |
| Financing | -27 |
| Net Cash Flow | +51 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 79.8% | 79.8% | 73.2% |
| FII | 1.1% | 0.9% | 0.6% |
| DII | 4.7% | 4.5% | 9.1% |
| Public | 9.9% | 10.6% | 10.1% |
| # Shareholders | 80,187 | 79,199 | 78,927 |
Promoter holding has slightly declined from 79.81% in Q4FY26 to 73.15% in Q1FY27, indicating minor dilution or promoter selling, though still majority-owned. Institutional ownership (FII) remains low at 0.62% in Q1FY27, down from 1.14% in Q3FY26, suggesting limited institutional accumulation. In contrast, DII holdings rose from 4.51% to 9.12% over the quarters, signaling growing interest from domestic institutional investors. The increasing number of shareholders (78,927 in Q1FY27) may reflect retail interest or index inclusion. Overall, while promoters remain dominant, there is a notable shift toward institutional and broader retail participation.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Revenue volatility persists despite margin resilience, with three consecutive YoY declines raising concerns about demand sustainability in core pharmaceutical segments. 2. High reliance on promoter-controlled governance may limit independent oversight, and the virtual AGM with no physical attendance or proxy voting could reduce shareholder engagement. 3. Low institutional ownership and limited analyst coverage may reduce market confidence and liquidity. 4. No forward guidance from management on revenue recovery or capital allocation strategy limits investor ability to assess near-term catalysts.
📋 Recent Filings
- Announcement2026-09-24Blue Jet Healthcare announced that its insider trading window will close on October 1, 2026, remaining shut until 48 hours after the unaudited standal…
- 🟡 voting results2026-09-22Blue Jet Healthcare shareholders approved all six AGM resolutions, including adoption of audited financials, a Re. 1.20 dividend, re-appointment of di…
- 🟡 Board Meeting2026-09-21Blue Jet Healthcare held its 58th AGM on September 21, 2026 via video conference, confirming quorum and reviewing FY2025-26 results. Shareholders appr…
- 🔴 annual report2026-08-18Blue Jet Healthcare announced its 58th Annual General Meeting on September 21, 2026, via video conferencing, with shareholders voting on key resolutio…
- 🟡 sustainability report2026-08-18Blue Jet Healthcare Limited (BLUEJET) released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 on August 18, 2026, disclos…
- 🟡 Board Meeting2026-08-03Blue Jet Healthcare announced board approval of Q1 FY26 unaudited results, reappointments of Akshay Arora as Whole-Time Director and Executive Chairma…
- 🔴 Corporate Action2026-08-03Blue Jet Healthcare announced its Q1 FY26 unaudited financial results, showing revenue of ₹2,931.13 crores and profit of ₹782.64 crores. The Board rea…
- 🔴 Financial Results2026-08-03Blue Jet Healthcare reported Q1 FY27 revenue of **₹2,931 million**, down 17% YoY but up 25% QoQ, with PAT margin at 27% and EBITDA margin at 33%. The …
- Announcement2026-07-28Blue Jet Healthcare announced an analyst and investor conference call on August 3, 2026 at 5:30 PM IST to discuss unaudited standalone financial resul…
- Announcement2026-07-20Blue Jet Healthcare announced it received the EcoVadis Silver Medal for sustainability excellence, placing it in the top 15% globally with a 77 score …
🧠 Analyst's Read
Blue Jet Healthcare shows signs of operational stabilization with margin improvement and strong liquidity, but revenue decline remains a key headwind. Investors should monitor the pace of sequential revenue recovery in upcoming quarters and the strategic use of the recently raised capital. The company’s strong governance and ESG profile support long-term resilience, but near-term growth visibility is limited without new product launches or market expansion signals.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when BLUEJET files new disclosures
Track BLUEJET filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BLUEJET — FreeFree account · 2 AI queries/day